Similar to our study, Kulkarni et al. reported that [68Ga]Ga-PSMA-11 PET-CT was superior to mpMRI at detecting LNI in intermediate-to-high-risk prostate cancer: for [68Ga]Ga-PSMA-11 PET-CT, the sensitivity was 80%, and the specificity was 90%, whereas, for mpMRI, the sensitivity was 44%, and the specificity was 79% [38]. The gene discussed is FOLH1; the disease is prostate carcinoma.